Our team came together with Habitat for Humanity to build and decorate two children’s playhouses, one for a preschool and one for a local community organization. A hands-on reminder of what’s possible when people show up with shared purpose.

CD24 defines a new way for macrophage checkpoint inhibition, with potential for greater selectivity and safety because it is highly expressed and often amplified in tumors but absent on red cells and platelets. Read more in Drug Target Review: bit.ly/48sZnIZ #immunotherapy

At #SITC2025, we will share ongoing research showing CD24 amplification correlates with poor survival across multiple cancers. The data highlights CD24 as both a macrophage checkpoint and potential biomarker for response to therapies like PHST001. www.pheast.com/pipeline/

Four years ago, we set out to change how cancer is treated. What began with a breakthrough discovery on CD24 is now a clinical-stage effort advancing macrophage-directed therapies that help the immune system “feast” on cancer. Thank you to all who support us on our mission!

Pheast will present a trial-in-progress poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26 in Boston. For more on #Targets25, visit: www.aacr.org/meeting/aacr...

The crew that sails together, prevails together. This summer, the Pheast team set sail for a day on the water – building trust, sharing laughs, and celebrating the spirit of collaboration that drives us. #PheastMode

For #InternationalPodcastDay, CEO Roy Maute reflects on the journey so far, as well as its future trajectory. Listen to this #BioHub episode for more about the company's first clinical trial and the science behind PHST001. open.spotify.com/episode/3u4i... podcasts.apple.com/us/podcast/e...

Pheast CEO Roy Maute’s talk at BioScience Forum, 𝙏𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 ‘𝘿𝙤𝙣’𝙩 𝙀𝙖𝙩 𝙈𝙚’ 𝙎𝙞𝙜𝙣𝙖𝙡𝙨 𝙛𝙤𝙧 𝙈𝙖𝙘𝙧𝙤𝙥𝙝𝙖𝙜𝙚-𝙈𝙚𝙙𝙞𝙖𝙩𝙚𝙙 𝘾𝙖𝙣𝙘𝙚𝙧 𝙏𝙝𝙚𝙧𝙖𝙥𝙮, will dive into PHST001 in clinical trials and next-gen immune modulation. For more info and to register, visit: www.biosf.org

Please join us in welcoming Susan Luebbe to #TeamPheast as our new VP of Clinical Operations! With a proven track record of leading global clinical studies and delivering for patients, Susan will help drive the next phase of clinical development for PHST001.

This #PrideMonth, our team gathered to reflect, create, and celebrate. We’re proud to stand with the LGBTQIA+ community, within our walls and beyond, and to take action toward equity. #Pride2025

We moved! As the Pheast team settles into our new space, we’re inspired by what drives us: a trailblazing spirit, empowered teams, and a passion for improving lives through science. Here’s to progress powered by purpose, rigor, and bold ideas. #PheastMode

Pheast CMO Dr. Raphaël Rousseau shares with ONCOLife how PHST001, our clinical-stage anti-CD24 antibody, is uniquely designed to engage innate immunity in high-need cancers. Read the interview here: healthandpharma.net/oncolife-new...

Can macrophage biology reshape cancer immunotherapy? Our CEO Roy Maute will discuss in this Drug Discovery World webinar how macrophage biology and CD24-targeting approaches could address gaps in the current #immunotherapy landscape. www.ddw-online.com/unpacking-th...

PHST001, our anti #CD24 #macrophage #checkpointinhibitor, has received Fast Track Designation from the FDA for ovarian cancer. We are currently enrolling the #clinicaltrial for PHST001. Read the release here: www.pheast.com/pheast-thera...

We’re proud to share that the first patient has been treated in our Phase 1 #clinicaltrial of PHST001, our anti #CD24 #macrophage #checkpointinhibitor. Huge thanks to our team, collaborators & the patients for making this milestone possible. www.pheast.com/pheast-thera...

We’re not just developing a new drug—we’re opening the door to an entirely new immune mechanism. Pheast CEO Roy Maute talks with 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 about macrophages, CD24, and our first clinical trial. deeptechdigest.com/biotech/base...